College of Nursing, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing, Ann Arbor, Michigan, United States.
Policy Polit Nurs Pract. 2021 May;22(2):126-133. doi: 10.1177/1527154421989609. Epub 2021 Feb 10.
Medicinal cannabis is legal in some form in 47 states, 3 United States territories, and the District of Columbia. An estimated three million Americans use cannabis for relief of a variety of illnesses, and this figure is expected to grow based on policy changes. However, cannabis remains illegal at the federal level as a Schedule I drug under the 1970 Controlled Substances Act. Schedule I classification of cannabis has impeded the advancement of research, leaving providers with little evidence-based information to educate their patients. Furthermore, the disparities in individual state laws create significant social and health inequities in gaining access to medicinal cannabis. Conflicting state and federal policies regarding medicinal cannabis create logistical and ethical dilemmas, and all U.S. stakeholders-patients, providers, and health delivery systems-may be impacted by conflicting federal and state policies. This brief addresses the impact of conflicting cannabis policies.
医用大麻在 47 个州、3 个美国领土和哥伦比亚特区以某种形式合法化。据估计,有 300 万美国人使用大麻来缓解各种疾病,而且随着政策的变化,这个数字预计还会增加。然而,大麻仍然是联邦一级的非法药物,根据 1970 年《管制药物法》被列为附表 I 药物。大麻被列为附表 I 药物的分类阻碍了研究的进展,使得提供者几乎没有基于证据的信息来教育他们的患者。此外,个别州法律之间的差异导致在获得医用大麻方面存在显著的社会和健康不平等。医用大麻的州和联邦政策之间存在冲突,这给医疗服务提供者带来了法律和伦理方面的困境,所有美国利益相关者——患者、提供者和医疗服务系统——都可能受到联邦和州政策冲突的影响。本简讯探讨了冲突的大麻政策的影响。